Matches in Wikidata for { <http://www.wikidata.org/entity/Q66075824> ?p ?o ?g. }
Showing items 1 to 29 of
29
with 100 items per page.
- Q66075824 description "clinical trial" @default.
- Q66075824 description "ensayu clínicu" @default.
- Q66075824 description "klinisch onderzoek" @default.
- Q66075824 description "клінічне випробування" @default.
- Q66075824 name "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 name "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 type Item @default.
- Q66075824 label "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 label "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 prefLabel "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 prefLabel "DP-R213 Phase 1 Pharmacokinetics Study" @default.
- Q66075824 P1132 Q66075824-6527C939-2930-46D6-8D09-20B06B1E9F8B @default.
- Q66075824 P1476 Q66075824-DCF132C8-79CB-430D-99AF-C915ED845010 @default.
- Q66075824 P2899 Q66075824-DFC8FE78-26B3-4A57-A685-53CA0898F3FD @default.
- Q66075824 P3098 Q66075824-47300FD4-F967-4653-B352-ABE605DF1CB4 @default.
- Q66075824 P31 Q66075824-6A72EEA6-C7A1-4AF3-8A08-71BF79A0C50C @default.
- Q66075824 P580 Q66075824-61D22973-C470-49C8-950C-9D683FC9B1B0 @default.
- Q66075824 P582 Q66075824-E930EB40-8399-4B96-8506-9BD4BEBC317D @default.
- Q66075824 P6099 Q66075824-552C06A4-88F7-4519-8573-6016C39D2059 @default.
- Q66075824 P8363 Q66075824-2026F0DB-4E96-4B80-BA2E-FDA6D2AD2185 @default.
- Q66075824 P1132 "+46" @default.
- Q66075824 P1476 "An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Fixed Dose Combination of Raloxifen/Cholecalciferol Compared With Coadministration of Raloxifen and Cholecalciferol in Healthy Male Subjects" @default.
- Q66075824 P2899 "+19" @default.
- Q66075824 P3098 "NCT03010267" @default.
- Q66075824 P31 Q30612 @default.
- Q66075824 P580 "2017-01-03T00:00:00Z" @default.
- Q66075824 P582 "2017-03-08T00:00:00Z" @default.
- Q66075824 P6099 Q5452194 @default.
- Q66075824 P8363 Q78089383 @default.